文献速递肝病

5-甲基四氢叶酸增强普萘洛尔对肝硬化患者门静脉压力的降低作用:一项随机安慰剂对照试验

5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
PubMed 文献 · J Hepatol · 2023-07-22

这项双盲随机安慰剂对照试验将60例HVPG≥12 mmHg的肝硬化患者按1:1分为5-MTHF+普萘洛尔组与安慰剂+普萘洛尔组,治疗90天。5-MTHF+普萘洛尔组HVPG下降幅度显著大于安慰剂+普萘洛尔组(20% vs 12.5%,p=0.028),且BH4更高、ADMA与tHcy更低。

要点

  • 5-MTHF+普萘洛尔较安慰剂+普萘洛尔进一步降低HVPG(20% vs 12.5%,p=0.028)。
  • 5-MTHF+普萘洛尔组BH4更高、ADMA与tHcy更低,提示一氧化氮生物利用度改善。
  • 作者认为该发现可为更大队列的验证研究提供基础。

核心结论

  • 在肝硬化门静脉高压患者中,5-MTHF给药显著增强了普萘洛尔所达到的HVPG下降。
  • 该效应似乎由肝微循环中一氧化氮生物利用度的改善所介导。

研究设计与样本

  • 双盲随机安慰剂对照试验,60例肝硬化且HVPG≥12 mmHg的患者按1:1随机接受5-MTHF+普萘洛尔或安慰剂+普萘洛尔治疗90天。
  • 治疗结束时复测HVPG及一氧化氮生物利用度标志物(BH4、ADMA、tHcy)。
  • 临床试验EudraCT编号:2014-002018-21。

主要发现

  • 两组基线临床与血流动力学数据及一氧化氮生物利用度标志物相似。
  • 两组HVPG均下降,但5-MTHF+普萘洛尔组下降幅度显著大于安慰剂+普萘洛尔组(百分比下降20 [29-9] vs 12.5 [22-0],p=0.028),肝血流量无差异。
  • 治疗结束时5-MTHF+普萘洛尔组较安慰剂+普萘洛尔组BH4更高(1,101.4 ± 1,413.3 vs 517.1 ± 242.8 pg/ml,p<0.001)。
  • 治疗结束时5-MTHF+普萘洛尔组较安慰剂+普萘洛尔组ADMA更低(109.3 ± 52.7 vs 139.9 ± 46.7 μmol/L,p=0.027)。
  • 治疗结束时5-MTHF+普萘洛尔组较安慰剂+普萘洛尔组tHcy更低(11.0 ± 4.6 vs 15.4 ± 7.2 μmol/L,p=0.010)。

临床怎么用

  • 作者认为该发现可为更大队列的验证研究提供基础,并可能影响肝硬化静脉曲张出血的未来预防管理。
  • 作者提出,用安全、可及、具成本效益的药物增强β受体阻滞剂的获益,可能改善肝硬化临床结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: β-blockers reduce hepatic venous pressure gradient (HVPG) by decreasing portal inflow, with no reduction in intrahepatic vascular resistance. 5-Methyltetrahydrofolate (5-MTHF) can prevent oxidative loss of tetrahydrobiopterin (BH4), a cofactor for endothelial nitric oxide synthase coupling. It also converts homocysteine (tHcy) into methionine and enables the degradation of asymmetric dimethylarginine (ADMA), an inhibitor of endothelial nitric oxide synthase. The aim of this study was to evaluate the effects of 5-MTHF in combination with propranolol on HVPG and nitric oxide bioavailability markers in patients with cirrhosis and portal hypertension. METHOD: Sixty patients with cirrhosis and HVPG ≥12 mmHg were randomized 1:1 to receive treatment with 5-MTHF+propranolol or placebo+propranolol for 90 days under double-blind conditions. HVPG and markers of nitric oxide bioavailability (BH4, ADMA and tHcy) were measured again at the end of treatment. RESULTS: Groups were similar in terms of baseline clinical and hemodynamic data and nitric oxide bioavailability markers. HVPG decreased in both groups, but the magnitude of the change was significantly greater in the group treated with 5-MTHF+propranolol compared to placebo+propranolol (percentage decrease, 20 [29-9] vs. 12.5 [22-0], p = 0.028), without differences in hepatic blood flow. At the end of treatment, 5-MTHF+propranolol (vs. placebo+propranolol) was associated with higher BH4 (1,101.4 ± 1,413.3 vs. 517.1 ± 242.8 pg/ml, p <0.001), lower ADMA (109.3 ± 52.7 vs. 139.9 ± 46.7 μmol/L, p = 0.027) and lower tHcy (μmol/L, 11.0 ± 4.6 vs. 15.4 ± 7.2 μmol/L, p = 0.010) plasma levels. CONCLUSION: In patients with cirrhosis and portal hypertension, 5-MTHF administration significantly enhanced the HVPG reduction achieved with propranolol. This effect appears to be mediated by improved nitric oxide bioavailability in the hepatic microcirculation. CLINICAL TRIAL EUDRACT NUMBER: 2014-002018-21. IMPACT AND IMPLICATIONS: Currently, the pharmacological prevention of cirrhosis complications due to portal hypertension, such as esophageal varices rupture, is based on the use of β-blockers, but some patients still present with acute variceal bleeding, mainly due to an insufficient reduction of portal pressure. In this study, we sought to demonstrate that the addition of folic acid to β-blockers is more effective in reducing portal pressure than β-blockers alone. This finding could represent the basis for validation studies in larger cohorts, which could impact the future prophylactic management of variceal bleeding in cirrhosis. Enhancing the benefit of β-blockers with a safe, accessible, cost-effective drug could improve clinical outcomes in cirrhosis, which in turn could translate into a reduction in the rates and costs of hospitalization, and ultimately into improved survival.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Vukotic R, Di Donato R, Roncarati G, et al. 5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial. J Hepatol. 2023. PMID: 37482222. doi:10.1016/j.jhep.2023.06.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。